N-Methyl-4-phenylpyridinium Scaffold-Containing Lipophilic Compounds Are Potent Complex I Inhibitors and Selective Dopaminergic Toxins
- 1 April 2019
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 10 (6) , 2977-2988
Abstract
Although the exact cause or causes of Parkinson’s disease (PD) are not fully understood, it is believed that environmental factors play a major role. The discovery that a synthetic chemical, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-derived N-methyl-4-phenylpyridinium (MPP+), recapitulates major pathophysiological characteristics of PD in humans has provided the strongest support for this possibility. While the mechanism of the selective dopaminergic toxicity of MPP+ has been extensively studied and is, in most respects, well accepted, several key aspects of the mechanism are still debatable. In the present study, we use a series of structurally related, novel, and lipophilic MPP+ derivatives [N-(2-phenyl-1-propene)-4-phenylpyridinium] to probe the mechanism of action of MPP+ using dopaminergic MN9D and non-neuronal HepG2 cells in vitro. Here we show that effective mitochondrial complex I inhibition is necessary and that the specific uptake through plasma membrane dopamine transporter is not essential for dopaminergic toxicity of MPP+ and related toxins. We also provide strong evidence to support our previous proposal that the selective vulnerability of dopaminergic cells to MPP+ and similar toxins is likely due to the high inherent propensity of these cells to produce excessive reactive oxygen species as a downstream effect of complex I inhibition. Based on the current and previous findings, we propose that MPP+ is the simplest of a larger group of unidentified environmental dopaminergic toxins, a possibility that may have major public health implications.Keywords
Funding Information
- Institutes of Health National Center for Research Resources (INBRE Program /P20 RR016475)
This publication has 44 references indexed in Scilit:
- A Guide to Neurotoxic Animal Models of Parkinson's DiseaseCold Spring Harbor Perspectives in Medicine, 2011
- Vesicular monoamine transporters: Structure‐function, pharmacology, and medicinal chemistryMedicinal Research Reviews, 2011
- Epidemiology and etiology of Parkinson’s disease: a review of the evidenceEuropean Journal of Epidemiology, 2011
- Determination of Mitochondrial Membrane Potential and Reactive Oxygen Species in Live Rat Cortical NeuronsJournal of Visualized Experiments, 2011
- Mitochondrial complex I inhibition is not required for dopaminergic neuron death induced by rotenone, MPP + , or paraquatProceedings of the National Academy of Sciences, 2008
- Application of a C. elegans Dopamine Neuron Degeneration Assay for the Validation of Potential Parkinson's Disease GenesJournal of Visualized Experiments, 2008
- Vesicular Monoamine Transporter Substrate/Inhibitor Activity of MPTP/MPP+ Derivatives: A Structure–Activity StudyJournal of Medicinal Chemistry, 2008
- Studies on the Characterization of the Inhibitory Mechanism of 4′‐Alkylated 1‐Methyl‐4‐Phenylpyridinium and Phenylpyridine Analogues in Mitochondria and Electron Transport ParticlesJournal of Neurochemistry, 1994
- Evaluation of the probe 2',7'-dichlorofluorescin as an indicator of reactive oxygen species formation and oxidative stressChemical Research in Toxicology, 1992
- A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye bindingAnalytical Biochemistry, 1976